Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Moderna Inc 325 BINNEY STREET CAMBRIDGE MA 02142 USA

www.modernatx.com Employees: 5,600 P: 617-714-6500 F: 617-583-1998

Description:

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

Key Statistics

Overview:

Market Capitalization, $K 22,124,444
Enterprise Value, $K 19,217,444
Shares Outstanding, K 383,240
Annual Sales, $ 6,848 M
Annual Net Income, $ -4,714 M
Last Quarter Sales, $ 241,000 K
Last Quarter Net Income, $ -1,279 M
EBIT, $ -4,635 M
EBITDA, $ -4,075 M
60-Month Beta 1.66
% of Insider Shareholders 15.70%
% of Institutional Shareholders 75.33%
Float, K 323,071
% Float 84.30%
Short Volume Ratio 0.51

Growth:

1-Year Return -41.70%
3-Year Return -82.32%
5-Year Return 239.39%
5-Year Revenue Growth 4,969.96%
5-Year Earnings Growth -149.09%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.33 on 08/01/24
Next Earnings Date 11/07/24
Earnings Per Share ttm -7.24
EPS Growth vs. Prev Qtr -8.47%
EPS Growth vs. Prev Year 8.01%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MRNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -21.35%
Return-on-Assets % -15.75%
Profit Margin % -68.84%
Debt/Equity 0.00
Price/Sales 3.27
Price/Cash Flow N/A
Price/Book 1.91
Book Value/Share 30.47
Interest Coverage -1.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar